Send feedback

GAA p.Arg464Ser

c.1392G>C · rs372786811 · VCV432217

Uncertain significance Expert panel
Classification
Uncertain significance
ClinVar
Review
Expert panel ★★★☆
ClinVar · 10 submitters
AlphaMissense
ambiguous
0.4182 · ACMG-weighted
gnomAD v4.1
Rare
ultra-rare (popmax 0.0186%, nfe)
Conditions
1
glycogen storage disease II

ClinGen expert panel — Lysosomal Diseases VCEP

Uncertain Significance for glycogen storage disease II. Applied ACMG criteria (verbatim):

PM2_Supporting

Curation rationale (ClinGen, verbatim)

The NM_000152.5c.1392G>C variant in GAA is a missense variant predicted to cause substitution of Arginine by Serine at amino acid 464 (p.Arg464Ser). The highest population minor allele frequency in gnomAD v4.1.0 is 0.00019 (219/1179922 alleles) in the European (non-Finnish) population, which is lower than the ClinGen LD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion. The computational predictor REVEL gives a score of 0.631 which is neither above nor below the thresholds predicting a damaging (>0.7) or benign (<0.5) impact on GAA function. Another missense variant c.1390A>T, p.Arg464Trp in the same codon has been reported in a patient with Pompe disease (ClinVar Variation ID: 843677). However, this variant has not yet met the criteria to be classified as pathogenic or likely pathogenic by the ClinGen LD VCEP. There is a ClinVar entry for this variant (Variation ID: 432217, 3-star review status) with 6 submitters classifying the variant as Uncertain Significance and 1 submitter classifying the variant as Likely Pathogenic. In summary, this variant meets the criteria to be classified as Uncertain Significance for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Disease Variant Curation Expert Panel (Specifications Version 2.0): PM2_Supporting. (Classification approved by the ClinGen Lysosomal Disease Variant Curation Expert Panel on November 17, 2025)

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.4182ambiguous
REVEL0.631indeterminate
SaProtLLR -8.65tolerated
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 1.4GERP -3.2, phastCons 1
Regional constrainto/e 1.03unconstrained · MANE · 15 kb · p 0.22 · regional, not allelic
Overall
CADD16.85PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes
Grpmax group 0.0186% European (non-Finnish) · 219/1,179,922 alleles
Filtering AF 0.0165% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.0157%
Overall 0.0147% 237/1,613,246 alleles · ultra-rare exomes 222/1,460,994 · genomes 15/152,252 · joint denominator
Ancestry group Frequency 1 in
Remaining individualsnot grpmax-eligible 0.0192% 5,206
European (non-Finnish)grpmax 0.0186% 5,388
Admixed American 0.005% 20,002
South Asian 0.00329% 30,356

Remaining individuals shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene
GAA
Protein
p.Arg464Ser
Coding
c.1392G>C
MANE Select
NM_000152
dbSNP
rs372786811
Type
single nucleotide variant
Location
chr17:80110010 (GRCh38)
Gene constraint
LOEUF 1.008 · pLI <0.01 (gnomAD)
Structure
AlphaFold pLDDT 92.32 · 19 PDB
Residue 464
an α-helix
Full GAA gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

glycogen storage disease II — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For Glycogen storage disease due to acid maltase deficiency (Orphanet):

Inheritance
Autosomal recessive
Onset
Adolescent, Adult, Antenatal, Childhood, Infancy, Neonatal
Prevalence
1-9 / 1 000 000 (Europe)

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/gaa-p-arg464ser (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown